Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome

Overview of attention for article published in Cancer Management and Research, October 2019

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 26 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 14 publications that cite this research output.

14

The most recent citing publications are shown below. View all 14 publications that cite this research output on Dimensions.

BeTTer Outcomes Workgroup Health Quality Initiative to optimize bone health for prostate cancer patients in the British Columbia Cancer System

Article in Canadian Urological Association Journal (August 2023)

Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer

Article in Journal of Clinical Medicine (August 2023)

Sarcopenia in Men With Bone-Predominant Metastatic Castration-Resistant Prostate Cancer Undergoing Ra-223 Therapy

Article in Clinical Genitourinary Cancer (January 2023)